Cardinal Health Inc.

Most of its revenue is recognized at the moment a physical product changes ownership, consistent with a business that earns by moving high volumes of goods rather than collecting recurring fees. A smaller layer comes from services billed as they are delivered, and a separate margin comes from discounts, rebates, and fees paid by generic-drug manufacturers, on top of the margin on the products themselves.

It carries relatively little in fixed property and equipment for the revenue it generates, with growth coming mostly from moving greater volume through existing infrastructure, though it also names specific, targeted projects, including new automated distribution centers and an expanded nuclear-pharmacy network, that selectively extend that base. Cash generation has been reliable enough, on average across recent years, to support a long-running and growing pattern of dividend payments, though that average can mask a weaker single year, including the most recent one.

Its own filings describe reliance on outside suppliers for the products, components, raw materials, and energy it needs, with inputs such as resins, pulp, cotton, and latex sourced from numerous suppliers across many countries. For some components or materials it relies on a single supplier, chosen for quality, cost, or availability, though which specific items are sole sourced is not spelled out.

A broad set of pharmacies, hospitals, specialty providers, laboratories, physician offices, and, through its at-Home business, individual patients rely on it for products and fulfillment. Within that base, one customer, CVS Health, is large enough that the company's own filings single it out by name as its top revenue source and a major source of receivables, and two named group purchasing organizations, Vizient and Premier, described as its largest such relationships, negotiate on behalf of many providers at once.

The general way it operates, high volume moving through a relatively light fixed-asset base, is shared by a large number of companies elsewhere in the economy, so scale and logistics reach are not unusual in themselves. Within pharmaceutical distribution specifically, its own filings name only McKesson and Cencora as national-scale rivals, and within medical products only Medline and Owens and Minor, a short list that says more about how concentrated those particular spaces are than about whether the network itself could be reproduced.

The clearest evidence on file is narrow: its largest customer, CVS Health, is tied to it through a joint generic-drug sourcing arrangement, Red Oak Sourcing, that runs on a fixed multi-year term rather than being open-ended, which structurally ties that specific relationship in place until the term runs out. Beyond that one arrangement, the company's filings do not disclose contract lengths, backlog, or retention figures for its broader customer base, so a general switching-cost story across all its customers is not something that can be seen here.

Cardinal Health's own filings describe its limits as regulatory requirements that slow how quickly it can replace a source of supply, contract and competitive limits on passing cost increases through to customers, supply-chain constraints in parts of the business, and the ability to attract and keep the staff the operation needs.

Its own filings single out one customer, CVS Health, as large enough in revenue and receivables to be named individually, and they record that another major customer relationship, with OptumRx, ended when its distribution contracts expired, showing that even large customer relationships are not permanent. The company also relies on a sole supplier for some unnamed components or materials, and the risks it lists first, in its own words, are regulatory and licensing requirements and the risk of product-quality issues, ahead of anything else in its disclosures. Earnings have also not been positive in every year on file, so scale by itself has not guaranteed profitability in every period.

Its own filings name a wide set of regulators, including the DEA and FDA for drug handling and federal health-program overseers, alongside state licensing boards, environmental and nuclear regulators, and customs authorities, so continued operation depends on staying inside many overlapping regimes at once rather than a single one. It also names direct exposure to tariffs, import and export controls, and customs rules, plus currency movements tied to the specific countries where it sources and sells.